2019 CYIR Finalized
60 Comments 1. Methamphetamine is a definite cause of PAH 2. A history of drug and toxin exposure should be part of the evaluation of PAH patients. 3. Dasatinib is a definite cause of PAH and should be avoided in patients with risk factors for PH. 4. Pharmacovigilance should play a major role in public health initiatives to prevent outbreaks of drug induced PAH. PEDIATRIC PULMONARY VASCULAR DISEASES Rosenzweig EB, Abman SH, Adatia I, Beghetti M, Bonnet D, Haworth S, Ivy DD, Berger RMF. Paediatric pulmonary arterial hypertension: updates on definition, classifica- tion, diagnostics and management. Eur Respir J. 2019 Jan 24;53(1). Summary The Pediatric Task Force of the 6th WSPH chose to fol- low the new proposed adult definition of PH for pediatric patients. Based on available genetic data, mutations in TBX4 and ACVRL1 appear enriched in pediatric hereditary and idiopathic PAH. Regarding genetic testing, it was recom- mended that this should be performed in expert centers with a genetic counselling group. Classification of pedi- atric PAH was also reviewed to stress differences in eti- ologies compared to adults. Patients with single ventricle physiology were recognized as an emerging phenotype and was included in group 5 of the clinical classifica- tion. Furthermore, separate designations were given to congenital/acquired cardiovascular conditions leading to post-capillary PH (group 2.4), developmental lung disorders (group 3.5), other pulmonary artery obstructions (group 4.2) and complex CHD (group 5.4). Regarding therapy, a trial of endothelin receptor antagonists and PDE5 inhibi- tors alone or in combination (if patient is considered high risk) is advisable, with further consideration for addition of inhaled or intravenous prostacyclin depending on clinical risk. Finally, the task force acknowledge possible role for palliative therapy with atrial septostomy or Potts shunt but acknowledged that further studies are required to deter- mine how these interventions should be prioritized. Comments 1. Pediatric PAH is defined as mPAP ⩾ 20mmHg, PAWP ⩽ 15mmHg and PVR ⩾ 3WU. 2. Mutations in TBX4 and ACVRL1 are enriched in pediatric hereditary and idiopathic PAH. 3. Clinical classification of pediatric PH includes etiologies differ- ent from those of adults. 4. Therapy should be driven on risk stratification and regular clinic assessment. 5. Atrial septostomy and Potts shunt can be considered in select- ed cases. OTHER ARTICLES OF INTEREST Mercurio V, Mukherjee M, Tedford RJ, Zamanian RT, Khair RM, Sato T, Minai OA, Torres F, Girgis RE, Chin K, Damico R, Kolb TM, Mathai SC, Hassoun PM. Improvement in Right Ventricular Strain with Ambrisentan and Tadalafil Upfront Therapy in Scleroderma-associated Pulmonary Arterial Hypertension. Am J Respir Crit Care Med. 2018 Feb 1;197(3):388-391. Budas GR, Boehm M, Kojonazarov B, Viswanathan G, Tian X, Veeroju S, Novoyatleva T, Grimminger F, Hinojosa- Kirschenbaum F, Ghofrani HA, Weissmann N, Seeger W, Liles JT, Schermuly RT. ASK1 Inhibition Halts Disease Progression in Preclinical Models of Pulmonary Arterial Hypertension. Am J Respir Crit Care Med. 2018 Feb 1;197(3):373-385. Mihai C, Antic M, Dobrota R, Bonderman D, Chadha- Boreham H, Coghlan JG, Denton CP, Doelberg M, Grünig E, Khanna D, McLaughlin VV, Müller-Ladner U, Pope JE, Rosenberg DM, Seibold JR, Vonk MC, Distler O. Factors associated with disease progression in early-diagnosed pulmonary arterial hypertension associated with sys- temic sclerosis: longitudinal data from the DETECT cohort. Ann Rheum Dis. 2018 Jan;77(1):128-132. Tang H, Babicheva A, McDermott KM, Gu Y, Ayon RJ, Song S, Wang Z, Gupta A, Zhou T, Sun X, Dash S, Wang Z, Balistrieri A, Zheng Q, Cordery AG, Desai AA, Rischard F, Khalpey Z, Wang J, Black SM, Garcia JGN, Makino A, Yuan JX. Endothelial HIF-2α contributes to severe pulmo- nary hypertension due to endothelial-to-mesenchymal transition. Am J Physiol Lung Cell Mol Physiol. 2018 Feb 1;314(2): L256-L275. Saito T, Miyagawa K, Chen SY, Tamosiuniene R, Wang L, Sharpe O, Samayoa E, Harada D, Moonen JAJ, Cao A, Chen PI, Hennigs JK, Gu M, Li CG, Leib RD, Li D, Adams CM, Del Rosario PA, Bill M, Haddad F, Montoya JG, Robinson WH, Fantl WJ, Nolan GP, Zamanian RT, Nicolls MR, Chiu CY, Ariza ME, Rabinovitch M. Upregulation of Human Endogenous Retrovirus-K Is Linked to Immunity and Inflammation in Pulmonary Arterial Hypertension. Circulation. 2017 Nov 14;136(20):1920-1935. Zabini D, Granton E, Hu Y, Miranda MZ, Weichelt U, Breuils Bonnet S, Bonnet S, Morrell NW, Connelly KA, Provencher S, Ghanim B, Klepetko W, Olschewski A, Kapus A, Kuebler WM. Loss of SMAD3 Promotes Vascular Remodeling in Pulmonary Arterial Hypertension via MRTF Disinhibition. Am J Respir Crit Care Med. 2018 Jan 15;197(2):244-260. UPDATE ON PULMONARY VASCULAR DISEASES
Made with FlippingBook
RkJQdWJsaXNoZXIy MTM1ODMw